Zyla Life Sciences Business Combination, Contingent Consideration, Liability, Noncurrent
Zyla Life Sciences had Business Combination, Contingent Consideration, Liability, Noncurrent of $14.47 million as of 2020-03-31, per its 10-Q filed 2020-05-14.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent · last filed 2020-05-14
- 2020-03-31: Business Combination, Contingent Consideration, Liability, Noncurrent $14.47M.
- 2019-12-31: Business Combination, Contingent Consideration, Liability, Noncurrent $14.40M.
- 2019-09-30: Business Combination, Contingent Consideration, Liability, Noncurrent $15.60M.
- 2019-06-30: Business Combination, Contingent Consideration, Liability, Noncurrent $15.20M.
| Period end | Business Combination, Contingent Consideration, Liability, Noncurrent |
|---|---|
| 2020-03-31 | $14.47M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $14.40M 10-Q · filed 2020-05-14 |
| 2019-09-30 | $15.60M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $15.20M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $13.80M 10-Q · filed 2019-05-17 |
| 2019-02-01 | $13.60M 10-Q · filed 2020-05-14 |
| 2019-01-31 | $13.60M 10-Q · filed 2019-08-13 |